Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to b...

by A’Hern Roger, DeBono Johann, Sandhu Shahneen, Kalaitzaki Eletheria, Usdin Martine, Hall Emma E
Published 2011-12-01